ClinicalTrials.gg
CompletedNCT06511570Updated Oct 18, 2024

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

A Phase 1 interventional study of sabirnetug (ACU193) and Sabirnetug + rHuPH20 in Alzheimer Disease, sponsored by Acumen Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Acumen Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,189th of 1,610
28 · median 73
Started
2024
with 113 others
Phase 1
304 of 1,941
31 open now
Registered
1,718th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,189th largest by enrollment of the 1,610 interventional ones that give a count, is one of 114 that started in 2024, is one of 304 in phase 1, and was the 1,718th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily consents to participate in this study and provides written before the start of any study assessments.
  2. Male and female participants ≥ 50 years of age.
  3. Females must be of non-, defined as:

    1. females must have had ≥12 months of spontaneous amenorrhea (with documented follicle-stimulating hormone (FSH) ≥40 milli international units (mIU)/mL) or
    2. Surgically sterile including those who have had a hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 months before the first dose of the study drug.
  4. (BMI) between 18 and 32 kg/m2 (inclusive), and weighs ≥54 kg.
  5. Screening vital signs (measured after participants have rested in a supine position for a minimum of 5 minutes) within the following ranges: heart rate: 40-100 beats per minute (bpm); systolic blood pressure (BP): 90-150 millimeter of mercury (mmHg); diastolic BP: 50-95 mmHg. Out-of-range vital signs may be repeated once at any time point during the study per Investigator discretion.
  6. Sperm-producing males in a sexual relationship with females of childbearing potential (FOCBPs) must use adequate (e.g., condom) and must not donate sperm, starting from Screening until 180 days after the last dose of the study drug (See Section 5.3).
  7. Must be willing to abstain from smoking while confined at the CTU.
  8. The participant is confirmed to have adequate venous access by study staff.
  9. Is willing and able to remain in the CTU for the entire duration of each confinement period and return for outpatient visits.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.
  2. Shows signs/symptoms of dementia or has a parent with a known autosomal dominant mutation causing familial AD.
  3. A clinically significant abnormal finding on the physical exam, medical history, clinical laboratory results or (ECG), or at Screening. The Investigator may repeat clinical laboratory tests once to assess any out-of-range values for clinical significance.

    1. Participants with a value >2.5 times the (ULN) or \<60% the lower limit of normal (LLN) or any other value of concern per the Investigator will be excluded.
    2. corrected for heart rate by Fridericia's cube root formula (QTcF) interval is >460ms in females, QTcF>450ms in males and has ECG findings considered normal or not clinically significant by the Investigator or designee at Screening.
  4. Suicide risk, as determined by meeting any of the following criteria:

    • Any suicide attempt or preparatory acts/behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening in the last six months.
    • Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening.
    • Significant risk of suicide, as judged by the site Investigator.
  5. Known allergy to biological products or known to any component of sabirnetug or hyaluronidase, including .
  6. Use of any experimental agent within 6 months of the first dose of study drug.
  7. Administration of vaccinations (e.g., SARS-CoV-2 [COVID-19], influenza) within 14 days of administration of the study drug.
  8. Use of any over the counter (OTC) medication, nutritional or dietary supplements, homeopathic preparations, herbal remedies such as St. John's Wort Extract, or vitamins within 14 days before the first dose of the study drug until EOS without evaluation and approval by the Investigator.
  9. Use of any prescription medication, starting from 14 days or 5 half-lives (whichever is longer) prior to the first dose of the study drug until EOS without evaluation and approval by the Investigator.
  10. Blood or plasma donation within 7 days before the first dose of the study drug until EOS. Blood/plasma donations should not be made for at least 90 days after the last dose of the study drug.
  11. Has any prior history of substance abuse or treatment (including alcohol) within the 2 years prior to the first study treatment administration.
  12. Regular alcohol consumption >14 units per week (1 unit=½ pint beer, 25 mL of 40% spirit or a 125-mL glass of wine).
  13. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates), cotinine, or alcohol.
  14. Has a positive test for surface antigen, antibody, or (HIV) at screening or has been previously treated for hepatitis B, hepatitis C, or HIV infection.
  15. Documented COVID-19 active infection or recent COVID-19 infection in the past 2 weeks.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Arm 1

    12 participants receive sabirnetug by intravenous infusion

    Drug: sabirnetug (ACU193)

  • Experimental
    Arm 2

    16 participants receive sabirnetug + rHuPH20 by subcutaneous injection

    Combination Product: Sabirnetug + rHuPH20

Interventions

06

What researchers measure

Primary outcomes

  1. Estimate blood levels of sabirnetug (ACU193)

    Cmax (Maximum concentration, determined directly from individual concentration-time data)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  2. Estimate time to reach maximum blood levels of sabirnetug (ACU193)

    Tmax (Time of the maximum concentration)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  3. Estimate blood levels of sabirnetug (ACU193), terminal rate

    λz (The observed terminal rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  4. Estimate time to reach half-life blood levels of sabirnetug (ACU193), half-life

    T1/2 (The observed terminal half-life)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  5. Estimate blood levels of sabirnetug (ACU193), concentration-time

    AUC168h (Area under the concentration-time curve during a one-week dosing interval)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  6. Estimate blood levels of sabirnetug (ACU193), last concentration-time

    AUClast (Area under the concentration-time curve from time zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  7. Estimate blood levels of sabirnetug (ACU193), infinity concentration-time

    AUCinf (Area under the concentration-time curve from time zero extrapolated to infinity)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  8. Estimate blood levels of sabirnetug (ACU193), extrapolation

    AUCExtrap (%)(The percentage of AUCinf based on extrapolation)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  9. Estimate blood levels of sabirnetug (ACU193), Clast

    Clast (The last quantifiable concentration determined directly from individual concentration-time data)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

  10. Estimate time to reach last blood levels of sabirnetug (ACU193)

    Tlast (Time of the last quantifiable concentration)

    Time frame: Group 1: Day 1 (predose) up to Day 43 Group 2: Day 1 (predose) up to Day 50

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Sep 2024, 2 months.

Of 163 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 2 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 22, 2024
StartActual
Jun 25, 2024
Primary completionActual
Sep 17, 2024
CompletionActual
Sep 17, 2024
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511570
Lead sponsor
Acumen Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jun 25, 2024
Primary completion
Sep 17, 2024
Completion
Sep 17, 2024
Last update
Oct 18, 2024

Study contacts

Eric Siemers, M.D.
study director · Acumen Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sabirnetug · Hyaluronidase (human recombinant)

Start the discussion